Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

AstraZeneca : EU drug regulators step up work to prepare for 'no deal' Brexit

share with twitter share with LinkedIn share with facebook
share via e-mail
07/20/2018 | 01:40pm CEST
FILE PHOTO: The headquarters of the European Medicines Agency (EMA), is seen in London

LONDON (Reuters) - Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit.

Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

That leaves a major gap, since British experts carry out around a fifth of the work for the centralised European Medicines Agency (EMA), the EU's equivalent of the U.S. Food and Drug Administration.

In addition, Britain's Medicines and Healthcare products Regulatory Agency also plays a pivotal role in Europe's decentralised system of drug supervision, which is based on mutual recognition.

"It's a real pity that we are going to lose the UK expertise, which is certainly very strong," said Hugo Hurts, executive director of the Netherlands Medicines Evaluation Board.

"It's a real challenge, but I'm not going to say there is not enough knowledge to replace that in the rest of the network," Hurts told Reuters.

Germany, Sweden and the Netherlands are among the other big contributors to the EU drug review process, alongside Britain.

The Dutch agency has already added more than a dozen extra staff, and drug regulators in other EU states are also hiring more people.

In addition, officials are exploring how more drug assessment work can be performed by multinational teams in future, rather than just one agency.

Despite a vote by UK members of parliament this week calling for Britain's continued participation in the Europe regulatory network for medicines, there is no certainty that any such deal will be reached.

That reflects the wider lack of clarity over Britain's future relationship with the world's biggest trading bloc after it leaves the EU next March.

"At the end of the day, the network has to be prepared for the worst-case scenario. If we are not prepared by March 29, 2019 for a 'no deal' Brexit then we would have done a very bad job," Hurts said.


Maintaining timely approvals for new drugs is crucial for pharmaceutical and biotechnology companies, which have dozens of experimental medicines due to be assessed in the next couple of years.

The Brexit-induced disruption also comes at a time when regulators are having to grapple with oversight of a range of new health technologies, such as gene therapy, and a slew of big data on health outcomes.

Global drug companies, including UK-based GlaxoSmithKline and AstraZeneca, have been vocal in calling for continued close EU-UK ties after Brexit. The issue is also important to many Japanese drugmakers that have made Britain their European base.

The EMA itself is being uprooted from London to Amsterdam, increasing the pressure on the system for overseeing drug safety. Although Amsterdam is more attractive than other locations that might have been chosen, the agency is still braced for significant staff departures.

A staff survey last year predicted 19 percent employee losses from the move to Amsterdam, and the EMA's executive director Guido Rasi said this was based on optimistic assumptions.

Meanwhile, individual drug companies are taking steps to prepare their supply lines in the event of a disorderly or no-deal Brexit that could threaten the smooth flow of products across borders.

AstraZeneca said this week it was increasing stockpiles of those medicines in Britain and Europe that could be affected by around 20 percent.

(Reporting by Ben Hirschler; Editing by Keith Weir)

By Ben Hirschler

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.36% 5589 Delayed Quote.9.14%
GLAXOSMITHKLINE -0.53% 1549.8 Delayed Quote.17.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
07/20ASTRAZENECA : EU drug regulators step up work to prepare for 'no deal' Brexit
07/18ASTRAZENECA : Increases Drug Stockpile in Preparation for Hard Brexit
07/18ASTRAZENECA : to stockpile drugs as Brexit 'safety net'
07/18ASTRAZENECA : 10.1% Potential Upside Indicated by Deutsche Bank
07/18Fetal gene therapy could treat neurodegenerative disease
07/16ASTRAZENECA : Swedish Business Appoints New CEO
07/16ADVAXIS : rises after FDA lifts clinical hold
07/12ASTRAZENECA : FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic ..
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
More news
News from SeekingAlpha
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars 
07/18AstraZeneca to stockpile drugs ahead of Brexit 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
Financials ($)
Sales 2018 22 201 M
EBIT 2018 5 245 M
Net income 2018 1 969 M
Debt 2018 14 506 M
Yield 2018 3,71%
P/E ratio 2018 39,35
P/E ratio 2019 31,73
EV / Sales 2018 4,82x
EV / Sales 2019 4,55x
Capitalization 92 447 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 74,8 $
Spread / Average Target 1,9%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.14%92 447
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171